|
Mumbai-based Sanjivani Paranterals has posted net profit of Rs. 6.17 crore during the fiscal year ended March 31, 2024, registering a growth of 36.8 per cent as compared to Rs. 4.51 crore reported in the previous fiscal year. The total revenue grew 52 per cent during the fiscal year to Rs. 54.92 crore as compared to Rs. 36.04 crore during the previous fiscal.
The net profit for the quarter ended March 31, 2024 stood at Rs. 1.26 crore, with a 27 per cent growth compared to around Rs. 1 crore registered in the same period of previous fiscal year. The total revenue for the quarter grew around 60 per cent to Rs. 12.92 crore, as compared to Rs. 8.08 crore reported during the corresponding quarter of previous fiscal year.
EBITDA of the company grew almost 60 per cent to Rs. 2.2 crore and the margin stood at 17.18 per cent during the quarter, said the company.
Revenue of injectables grew 52.90 per cent year-on-year to Rs. 8.1 crore, while oral segment grew 66.23 per cent. Nutraceuticals business reported 137 per cent growth, added the company.
Ashwani Khemka, chairman and managing director of the company said, “Looking ahead, we are excited about the opportunities that lie ahead for Sanjivani Parenteral. Our strategic investments in expansion into new geographies, and the introduction of innovative products have positioned us for continued success and sustainable growth”.
“As we navigate the evolving healthcare landscape, we remain steadfast in our commitment. The company is on track on achieving its target for future,” added Khemka.
Exports constituted 73 per cent of total revenue, with the core markets of CIS (including Russia), Middle East and Africa and Latin America accounted for 66.85 per cent, added the company.
The company has two manufacturing plants at Navi Mumbai and Dehradun, and it specialises on manufacturing and distribution of high-quality parenteral and oral solid products. The company caters various therapeutic segments including central nervous system, cardiovascular system, antibiotics, gastroenterology, anti-diabetics and anti-allergic, among others.
|